

業績目録（令和4年）

大学院科目名：分子診断・治療医学

I 著書 なし

II 総説 なし

III 原著

1. Yasuda T, Sanada M, Kawazu M, Kojima S, Tsuzuki S, Ueno H, Iwamoto E, Iijima-Yamashita Y, Yamada T, Kanamori T, Nishimura R, Kuwatsuka Y, Takada S, Tanaka M, Ota S, Dobashi N, Yamazaki E, Hirose A, Murayama T, Sumi M, Sato S, Tange N, Nakamura Y, Katsuoka Y, Sakaida E, Kawamata T, Iida H, Shiraishi Y, Nannya Y, Ogawa S, Taniwaki M, Asou N, Hatta Y, Kiyoi H, Matsumura I, Horibe K, Mano H, Naoe T, Miyazaki Y, Hayakawa F. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations. *Blood* 139(12):1850-1862, 2022. (IF= 25.669)
2. Permatasari HK, Nakahata S, Ichikawa T, Fauzi YR, Kiyonari H, Shide K, Kameda T, Shimoda K, Ono M, Taki T, Taniwaki M, Futakuchi M, Morishita K. Oncogenic isoform switch of tumor suppressor BCL11B in adult T-cell leukemia/lymphoma. *Exp Hematol.* 111:41-49, 2022. (IF= 8.593)
3. Kaneko H, Shimura K, Yoshida M, Matsumoto Y, Kobayashi T, Uchiyama H, Kuroda J, Taniwaki M. Serum albumin levels strongly predict survival outcome of elderly patients with diffuse large B-cell lymphoma treated with rituximab-combined chemotherapy. *Int J Hematol Oncol Stem Cell Res.* 16(1):1-8., 2022. (IF= 0.239)
4. Iida H, Imada K, Ueda Y, Kubo K, Yokota A, Ito Y, Kiguchi T, Hata T, Nawa Y, Ikezoe T, Uchida T, Morita Y, Kawashima I, Chiba M, Morimoto K, Hirooka S, Miyazaki Y, Ohno R, Naoe T; Study Group. A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia. *Int J Hematol.* 115(5):694-703, 2022. (IF= 2.324)

5. Muramatsu A, Kobayashi T, Kawaji-Kanayama Y, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida SI, Shimazaki C, Mizutani S, Tsukamoto T, Shimura Y, Taniwaki M, Teramukai S, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma. *Leuk Lymphoma*. 63(7):1678-1685, 2022. (血液内科学との共同研究) (IF= 2.996)
6. Isa R, Horinaka M, Tsukamoto T, Mizuhara K, Fujibayashi Y, Taminishi-Katsuragawa Y, Okamoto H, Yasuda S, Kawaji-Kanayama Y, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Sakai T, Kuroda J. The rationale for the dual-targeting therapy for RSK2 and AKT in multiple myeloma. *Int J Mol Sci*. 2022 Mar 8;23(6):2919. (血液内科学との共同研究) (IF= 6.208)
7. Kawaji-Kanayama Y, Muramatsu A, Sasaki N, Shimura K, Kiyota M, Fuchida S, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Mizutani S, Nakao M, Kaneko H, Kawata E, Hirakawa K, Takahashi R, Shimazaki C, Uchiyama H, Uoshima N, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study. *Int J Hematol*. 115(3):350-362, 2022. (血液内科学との共同研究) (IF= 2.324)
8. Kawaji-Kanayama Y, Kobayashi T, Muramatsu A, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida SI, Shimazaki C, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Shimura Y, Horiike S, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients. *Cancer Rep (Hoboken)*. 2022 Feb;5(2):e1476. (血液内科学との共同研究) (IF= 0.768)

1. Mizuhara K, Kobayashi T, Nakao M, Takahashi T, Kaneko H, Shimura K, Hirakawa H, Uoshima N, Kamitsuji Y, Wada K, Kawata E, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Mizutani S, Shimura Y, Taniwaki M, Kuroda J. EHA-1062. Watchful waiting is an acceptable treatment option for primary ocular adnexal mucosa associated lymphoid tissue lymphoma: A retrospective study. EHA (European Hematology Association) 2022 Hybrid Congress. May 1-August 15, 2022 (血液内科学との共同研究)

V 研究助成（競争的研究助成金）

総額 30 万円

財団等からの助成

代表（総額）・小計 30 万円

- 1 一般社団法人日本血液学会 研究助成

令和 4 (2022) 年度

難治性 B 細胞リンパ腫における新規分子機構の解明：染色体腕内欠失によるキメラ遺伝子，遺伝子内エクソン再配列，連結遺伝子，LncRNA PVT1 キメラの解析

助成金額 30 万円